Markets
MA Stock Indexes
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
AMPIO PHARMA (NQ: AMPE)
4.820 USD  +0.150 (+3.21%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about AMPIO PHARMA
 
< Previous 1 2 3 Next >
Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
May 13, 2013
from PR Newswire
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee
April 25, 2013
from PR Newswire
Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion™ for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun.
April 02, 2013
from PR Newswire
Free Research Reports on AEZS, AMPE, ELN and MDCO Issued by the Bedford Report
March 12, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Ampio Receives FDA Acceptance of its Patient Outcome for Premature Ejaculation (POPE) Questionnaire, Paving the Way for its US Pivotal Trial on Zertane™
March 11, 2013
from PR Newswire
LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals
March 07, 2013
Optina Is Currently in a Pivotal Phase IIb Trial -- First Oral Drug for Diabetic Macular Edema; Phase II Run-In Trial for Ampion to Treat Osteoarthritis of the Knee to Begin in 2013; Available for... Read More
from Marketwired News Releases
Ampio Pharmaceuticals Initiates Clinical Trial of Optina™ in Diabetic Macular Edema (DME): First Patient Dosed
February 27, 2013
from PR Newswire
Ampio Pharmaceuticals Modifies Ampion™ IND for Osteoarthritis of the Knee to Include A Dose Escalation Run-In Study and Prepares to Launch Pivotal Clinical Trial
February 25, 2013
from PR Newswire
Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
February 11, 2013
from PR Newswire
Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
January 22, 2013
from PR Newswire
Ampio Pharmaceuticals Announces Active IND for Optina™ for the Treatment of Diabetic Macular Edema (DME)
January 22, 2013
from PR Newswire
Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
November 28, 2012
from PR Newswire
Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
November 14, 2012
from PR Newswire
Treatments and Drugs for Deadly or Debilitating Diseases May See Faster Approval Process
October 18, 2012
The Paragon Report Provides Stock Research on Ampio Pharmaceuticals and ISIS Pharmaceuticals Read More
from Marketwired News Releases
Faster FDA Review Process a Contributing Factor to Biotech Industry's Rise in 2012
September 21, 2012
The Paragon Report Provides Stock Research on Ampio Pharmaceuticals and Astex Pharmaceuticals Read More
from Marketwired News Releases
Ampio Provides Update of Manufacturing Plans for Zertane™
September 12, 2012
from PR Newswire
Ampio announces successful Pre-IND meeting with the Ophthalmology Division of the FDA on Optina™ for the treatment of Diabetic Macular Edema
August 01, 2012
from PR Newswire
Ampio Pharmaceuticals Announces Closing of Public Offering
July 18, 2012
from PR Newswire
Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
July 16, 2012
from PR Newswire
Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
July 13, 2012
from PR Newswire
Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
July 12, 2012
from PR Newswire
Ampio Pharmaceuticals Announces Proposed Public Offering
July 12, 2012
from PR Newswire
Highlights of significant results on Orally administered Optina™ for Diabetic Macular Edema (DME), including results for visual acuity.
July 09, 2012
from PR Newswire
Ampio's CEO and CSO Send Message to Shareholders
July 03, 2012
from PR Newswire
Ampio Contracts with Syngene to Manufacture Zertane-ED™, its Recently Patented Combination Drug to Treat both Premature Ejaculation (PE) and Erectile Dysfunction (ED)
July 02, 2012
Potential Distribution Partners for Sexual Dysfunction Drug Portfolio Increase Read More
from PR Newswire
Ampio Reports Successful Type B Pre-IND Meeting with the FDA for its Drug Zertane™ to treat Premature Ejaculation (PE)
June 21, 2012
from PR Newswire
Ampio Announces Positive Clinical Trial Results for the Treatment of Diabetic Macular Edema with Orally Administered Optina™
June 11, 2012
Confirmed July 2012 pre-IND FDA meeting scheduled Read More
from PR Newswire
Ampio Pharmaceuticals Keeping Investors Interested, Says VFC's Stock House
June 11, 2012
from EmailWire.Com Press Releases
VFC's Stock House Weekly Stock Watch, Week Of June 11th
June 10, 2012
from EmailWire.Com Press Releases
Ampio Patent Protection for Optina™ Expands to Include Europe
May 31, 2012
from PR Newswire
< Previous 1 2 3 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here